PCSK9estäjiä

PCSK9estäjiä, also known as PCSK9 inhibitors, are a class of medications used to lower cholesterol levels, particularly low-density lipoprotein (LDL) cholesterol. They work by targeting a protein called PCSK9. This protein normally binds to LDL receptors on the surface of liver cells and promotes their degradation. By reducing the number of LDL receptors, PCSK9 effectively limits the liver's ability to remove LDL cholesterol from the bloodstream.

PCSK9 inhibitors are typically monoclonal antibodies that bind to PCSK9, preventing it from interacting with LDL receptors. This binding action increases the number of LDL receptors available on the liver cell surface, leading to a significant reduction in circulating LDL cholesterol.

These drugs are generally administered via injection, either subcutaneously or intravenously, and are often prescribed for individuals with familial hypercholesterolemia or those who have not achieved their LDL cholesterol goals with statins and other lipid-lowering therapies, especially those at high risk for cardiovascular disease. Common PCSK9 inhibitors include evolocumab and alirocumab. While generally well-tolerated, potential side effects can include injection site reactions, flu-like symptoms, and, rarely, neurological events. Their development represents a significant advancement in the management of hypercholesterolemia and the prevention of atherosclerotic cardiovascular disease.